Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312255 · ClinicalTrials.gov registry record · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
A NA study of Plasma Cell Myeloma and Refractory Plasma Cell Myeloma, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 175
- Enrollment target
- 1
- Study location
NCT05312255 is a NA study of Plasma Cell Myeloma and Refractory Plasma Cell Myeloma that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 175 participants, below the 203-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05312255, a NA study of Plasma Cell Myeloma and Refractory Plasma Cell Myeloma, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 175 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BEHAVIORAL Behavioral Intervention
- DRUG Propranolol
- DRUG Beta-Adrenergic Antagonist
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2027-06-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312255
The ClinicalTrials.gov registry entry for NCT05312255 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (14% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05312255 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05312255 about?
NCT05312255 is a clinical study titled "Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma". This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system ...
What is the current status of trial NCT05312255?
This trial is currently recruiting. It is a NA study. The enrollment target is 175 participants. The study started on 2022-06-28. Estimated completion is 2027-06-28.
What conditions does trial NCT05312255 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT05312255?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Behavioral Intervention (BEHAVIORAL), Propranolol (DRUG), Beta-Adrenergic Antagonist (DRUG).
Who is sponsoring clinical trial NCT05312255?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312255 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
RECRUITING · NA
-
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
ACTIVE NOT RECRUITING · NA
-
Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy
COMPLETED · NA
-
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
COMPLETED · NA
-
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RECRUITING · Phase 3
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.